Klaus Krüger

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study

J. Detert, H. Bastian, Joachim Listing et al. · Annals of the Rheumatic Diseases · 2012 · 188 citations

Life Sciences, Clinical Sciences, Pharmacotherapy +17

Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach

Rieke Alten, Klaus Krüger, J. Rellecke et al. · Patient Preference and Adherence · 2016 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis

Klaus Krüger, U. von Hinüber, Florian Meier et al. · Rheumatology International · 2018 · 51 citations

Medicine, Clinical Sciences, Internal Medicine +10

New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis – Implications from the prospective multicenter VADERA II study

Matthias Englbrecht, Rieke Alten, Martin Aringer et al. · PLoS ONE · 2019 · 45 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany

Klaus Krüger, Gerd R Burmester, Siegfried Wassenberg et al. · BMJ Open · 2018 · 43 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16